Peregrine Pharmaceuticals Reports Financial Results for Fiscal...(---- ---- LIABILITIES AND ST...),Health

Date:7/14/2009

---- ---- LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $3,518,000 $2,060,000 Accrued clinical trial site fees 955,000 237,000 Accrued legal and accounting fees 667,000 450,000 Accrued royalties and license fees 182,000 222,000 Accrued payroll and related costs 1,580,000 1,084,000 Capital lease obligation, current portion 17,000 22,000 Notes payable, current portion and net of discount 1,465,000 - Deferred revenue 3,776,000 2,196,000 Deferred government contract revenue 3,871,000 - Customer deposits 2,287,000 838,000 Other current liabilities 546,000 331,000 ------- ------- Total current liabilities 18,864,000 7,440,000 Capital lease obligation, less current portion 4,000 22,000 Notes payable, less current portion and net of discount 3,208,000 - Other long-term liabilities 150,000 - Commitments and contingencies STOCKHOLDERS' EQUITY: Preferred stock - $.001 par value; authorized 5,000,000 shares; non-voting; nil shares outstanding - - Common stock - $.001 par value; authorized 325,000,000 shares; outstanding - 227,688,555 and 226,210,617, respectively 227,000 226,000 Additional paid-in-capital 248,034,000 246,205,000 Accumulated deficit
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer